[go: up one dir, main page]

CY1110990T1 - Παραγωγα αδενοσινης ως αγωνιστες υποδοχεων α2α - Google Patents

Παραγωγα αδενοσινης ως αγωνιστες υποδοχεων α2α

Info

Publication number
CY1110990T1
CY1110990T1 CY20101101154T CY101101154T CY1110990T1 CY 1110990 T1 CY1110990 T1 CY 1110990T1 CY 20101101154 T CY20101101154 T CY 20101101154T CY 101101154 T CY101101154 T CY 101101154T CY 1110990 T1 CY1110990 T1 CY 1110990T1
Authority
CY
Cyprus
Prior art keywords
racers
receptor
adenosine
stereoisomers
compounds
Prior art date
Application number
CY20101101154T
Other languages
English (en)
Inventor
Robin Alec Fairhurst
Roger John Taylor
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1110990T1 publication Critical patent/CY1110990T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Μια ένωση του χημικού τύπου (I), ή στερεοϊσομερή ή φαρμακευτικώς αποδεκτά άλατα αυτής, χημικός τύπος (1), ή στερεοϊσομερή ή φαρμακευτικώς αποδεκτά άλατα αυτού, όπου τα A, U1, U2, R1a, R1b, R2 και R5 έχουν τις σημασίες όπως υποδείχθηκε στην περιγραφή, είναι χρήσιμα για την αντιμετώπιση καταστάσεων που μεσολαβούνται από την ενεργοποίηση των υποδοχέων Α2Α της αδενοσίνης, συγκεκριμένα φλεγμονωδών ή αποφρακτικών νοσημάτων των αεραγωγών. Φαρμακευτικά σκευάσματα που περιέχουν αυτές τις ενώσεις και μια διαδικασία για την παρασκευή των ενώσεων, περιγράφονται επίσης.
CY20101101154T 2006-09-14 2010-12-15 Παραγωγα αδενοσινης ως αγωνιστες υποδοχεων α2α CY1110990T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06120706A EP1903044A1 (en) 2006-09-14 2006-09-14 Adenosine Derivatives as A2A Receptor Agonists
EP07803477A EP2066669B1 (en) 2006-09-14 2007-09-13 Adenosine derivatives as a2a receptor agonists

Publications (1)

Publication Number Publication Date
CY1110990T1 true CY1110990T1 (el) 2015-06-11

Family

ID=37622170

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101101154T CY1110990T1 (el) 2006-09-14 2010-12-15 Παραγωγα αδενοσινης ως αγωνιστες υποδοχεων α2α

Country Status (31)

Country Link
US (1) US8188100B2 (el)
EP (2) EP1903044A1 (el)
JP (1) JP2010503639A (el)
KR (1) KR20090040386A (el)
CN (1) CN101511831B (el)
AR (1) AR062768A1 (el)
AT (1) ATE481404T1 (el)
AU (1) AU2007296227A1 (el)
BR (1) BRPI0716936A2 (el)
CA (1) CA2662104A1 (el)
CL (1) CL2007002658A1 (el)
CR (1) CR10621A (el)
CY (1) CY1110990T1 (el)
DE (1) DE602007009272D1 (el)
DK (1) DK2066669T3 (el)
ES (1) ES2353141T3 (el)
HK (1) HK1131392A1 (el)
HR (1) HRP20100694T1 (el)
IL (1) IL197153A0 (el)
MA (1) MA30722B1 (el)
MX (1) MX2009002811A (el)
NO (1) NO20091244L (el)
PE (1) PE20081151A1 (el)
PL (1) PL2066669T3 (el)
PT (1) PT2066669E (el)
RU (1) RU2009113668A (el)
SI (1) SI2066669T1 (el)
TN (1) TN2009000084A1 (el)
TW (1) TW200821324A (el)
WO (1) WO2008031875A1 (el)
ZA (1) ZA200901036B (el)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ545787A (en) * 2001-10-01 2007-12-21 Univ Virginia 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
JP2008520744A (ja) 2004-11-19 2008-06-19 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 抗炎症性ピラゾロピリミジン
GB0500785D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
WO2007120972A2 (en) * 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
PT2004654E (pt) 2006-04-04 2013-08-27 Univ California Derivados de pirazolopirimidina para utilização como antagonistas da quinase
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
PT2013211E (pt) * 2006-04-21 2012-06-21 Novartis Ag Derivados de purina para utilização como agonistas de receptores a2a de adenosina
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
US8188063B2 (en) 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
CA2657973A1 (en) * 2006-06-27 2008-01-03 Biovitrum Ab (Publ) Therapeutic compounds
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
AU2007316715A1 (en) * 2006-11-10 2008-05-15 Novartis Ag Cyclopentene diol monoacetate derivatives
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
AU2008313789A1 (en) * 2007-10-17 2009-04-23 Novartis Ag Purine derivatives as adenosine AL receptor ligands
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
NZ613219A (en) 2008-01-04 2014-11-28 Intellikine Llc Heterocyclic containing entities, compositions and methods
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
JP5547099B2 (ja) 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
MX2011000216A (es) 2008-07-08 2011-03-29 Intellikine Inc Inhibidores de cinasa y metodos para su uso.
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
ES2570429T3 (es) 2008-10-16 2016-05-18 Univ California Inhibidores de heteroaril quinasa de anillo condensado
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
CN102573846B (zh) 2009-08-17 2015-10-07 因特利凯公司 杂环化合物及其用途
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
WO2011146882A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2824197C (en) 2011-01-10 2020-02-25 Michael Martin Processes for preparing isoquinolinones and solid forms of isoquinolinones
JP6130305B2 (ja) 2011-02-23 2017-05-17 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせおよびそれらの使用
JP6027610B2 (ja) 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環式化合物及びその使用
MX2014000648A (es) 2011-07-19 2014-09-25 Infinity Pharmaceuticals Inc Compuestos heterociclicos y sus usos.
MX2014002542A (es) 2011-08-29 2014-07-09 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
JP6342805B2 (ja) 2011-09-02 2018-06-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
EP2900673A4 (en) 2012-09-26 2016-10-19 Univ California IRE1 MODULATION
IL291945A (en) 2012-11-01 2022-06-01 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9359365B2 (en) 2013-10-04 2016-06-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
CN105012318B (zh) * 2014-04-17 2020-02-11 沈华浩 磺酰胺类化合物在气道慢性炎症性疾病中的应用
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2998469A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
IL261606B (en) 2016-03-16 2022-09-01 Kura Oncology Inc Substituted inhibitors of menin-mll and methods of use
EP3429585B1 (en) 2016-03-16 2021-11-24 Kura Oncology, Inc. Bridged bicyclic inhibitors of menin-mll and methods of use
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN109640999A (zh) 2016-06-24 2019-04-16 无限药品股份有限公司 组合疗法
WO2018175746A1 (en) 2017-03-24 2018-09-27 Kura Oncology, Inc. Methods for treating hematological malignancies and ewing's sarcoma
WO2018226976A1 (en) 2017-06-08 2018-12-13 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
US11649251B2 (en) 2017-09-20 2023-05-16 Kura Oncology, Inc. Substituted inhibitors of menin-MLL and methods of use
WO2019062803A1 (zh) 2017-09-28 2019-04-04 基石药业 作为a2a受体抑制剂的并环类衍生物

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1528382A (en) * 1974-12-26 1978-10-11 Teijin Ltd Cyclopentene diols and acyl esters thereof and processes for their preparation
US4738954A (en) * 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
US4873360A (en) * 1986-07-10 1989-10-10 Board Of Governors Of Wayne State University Process for the preparation of cyclopentanoids and novel intermediates produced thereby
US4954504A (en) * 1986-11-14 1990-09-04 Ciba-Geigy Corporation N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity
IL84414A0 (en) 1986-11-14 1988-04-29 Ciba Geigy Ag N9-cyclopentyl-substituted adenine derivatives
JP2586897B2 (ja) 1987-03-09 1997-03-05 富士薬品工業株式会社 光学活性なシス−シクロペンテン−３，５−ジオ−ルモノエステルの製造法
ES2095960T3 (es) 1990-09-25 1997-03-01 Rhone Poulenc Rorer Int Compuestos que tienen propiedades antihipertensivas y antiisquemicas.
IT1254915B (it) 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
US5688774A (en) * 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
US5691188A (en) * 1994-02-14 1997-11-25 American Cyanamid Company Transformed yeast cells expressing heterologous G-protein coupled receptor
EA000884B1 (ru) * 1996-01-02 2000-06-26 Рон-Пуленк Рорер Фармасьютикалз Инк. Способ получения 2,4-дигидроксипиридина и 2,4-дигидрокси-3-нитропиридина
US6376472B1 (en) * 1996-07-08 2002-04-23 Aventis Pharmaceuticals, Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
WO1998050047A1 (en) * 1997-05-09 1998-11-12 Trustees Of The University Of Pennsylvania Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
JP3933870B2 (ja) 1998-06-23 2007-06-20 グラクソ グループ リミテッド ２−（プリン−９−イル）−テトラヒドロフラン−３，４−ジオール誘導体
GB9813535D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813554D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813540D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
ES2264826T3 (es) 1998-10-16 2007-01-16 Pfizer Inc. Derivados de adenina.
DK1140933T3 (da) * 1998-12-31 2004-12-20 Aventis Pharma Inc Fremgangsmåde til fremstilling af N6-substituerede deaza-adenosinderivater
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6586413B2 (en) * 1999-11-05 2003-07-01 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
GB0003960D0 (en) 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
AU2002219497B2 (en) * 2001-01-16 2004-08-26 Can-Fite Biopharma Ltd. Use of an adenosine A3 receptor agonist for inhibition of viral replication
GB2372741A (en) 2001-03-03 2002-09-04 Univ Leiden C2,8-Disubstituted adenosine derivatives and their different uses
US20040162422A1 (en) * 2001-03-20 2004-08-19 Adrian Hall Chemical compounds
EP1258247A1 (en) * 2001-05-14 2002-11-20 Aventis Pharma Deutschland GmbH Adenosine analogues for the treatment of insulin resistance syndrome and diabetes
NZ545787A (en) 2001-10-01 2007-12-21 Univ Virginia 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
US7414036B2 (en) * 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
US20090170803A1 (en) 2002-04-10 2009-07-02 Linden Joel M Adjunctive treatment of biological diseases
ATE363907T1 (de) 2003-12-29 2007-06-15 Can Fite Biopharma Ltd Verfahren zur behandlung von multipler sklerose
SG144146A1 (en) 2004-03-05 2008-07-29 Cambridge Biotechnology Ltd Adenosine receptor agonists
US7396825B2 (en) 2004-05-03 2008-07-08 University Of Virginia Patent Foundation Agonists of A2A adenosine receptors for treatment of diabetic nephropathy
AR049384A1 (es) * 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
ES2432113T3 (es) 2004-07-28 2013-11-29 Can-Fite Biopharma Ltd. Agonistas del receptor de adenosina A3 para el tratamiento de trastornos del ojo seco, incluido el síndrome de Sjogren
US7825102B2 (en) * 2004-07-28 2010-11-02 Can-Fite Biopharma Ltd. Treatment of dry eye conditions
AU2005285284B2 (en) * 2004-09-09 2011-06-02 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Purine derivatives as A3 and A1 adenosine receptor agonists
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
US20080051364A1 (en) * 2004-11-08 2008-02-28 Pninna Fishman Therapeutic Treatment of Accelerated Bone Resorption
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
DK1848718T3 (da) * 2005-02-04 2012-08-27 Millennium Pharm Inc E1 aktiveringsenzymhæmmere
GB0505219D0 (en) * 2005-03-14 2005-04-20 Novartis Ag Organic compounds
GB0514809D0 (en) * 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
US20080300213A1 (en) * 2005-11-30 2008-12-04 Pnina Fishman Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment
KR101383228B1 (ko) * 2006-01-26 2014-04-09 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 레프리젠티드 바이 더 세크러터리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비스즈 Ａ3 아데노신 수용체 알로스테릭 조절제
ES2390921T3 (es) * 2006-02-02 2012-11-19 Millennium Pharmaceuticals, Inc. Inhibidores de la enzima activadora E1
US20080027022A1 (en) * 2006-02-08 2008-01-31 Linden Joel M Method to treat gastric lesions
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607954D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
PT2013211E (pt) * 2006-04-21 2012-06-21 Novartis Ag Derivados de purina para utilização como agonistas de receptores a2a de adenosina
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607951D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607948D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607945D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
US8008307B2 (en) * 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
AU2007316715A1 (en) * 2006-11-10 2008-05-15 Novartis Ag Cyclopentene diol monoacetate derivatives
WO2008124150A1 (en) * 2007-04-09 2008-10-16 University Of Virginia Patent Foundation Method of treating enteritis, intestinal damage, and diarrhea from c. difficile with an a2a adenosine receptor agonist
US20080262001A1 (en) * 2007-04-23 2008-10-23 Adenosine Therapeutics, Llc Agonists of a2a adenosine receptors for treating recurrent tumor growth in the liver following resection
US8153781B2 (en) * 2007-06-29 2012-04-10 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Dendrimer conjugates of agonists and antagonists of the GPCR superfamily
AU2008313789A1 (en) * 2007-10-17 2009-04-23 Novartis Ag Purine derivatives as adenosine AL receptor ligands
US20090181934A1 (en) * 2007-10-17 2009-07-16 Novartis Ag Organic Compounds
WO2009061516A1 (en) * 2007-11-08 2009-05-14 New York University School Of Medicine Medical implants containing adenosine receptor agonists and methods for inhibiting medical implant loosening
EA201001135A1 (ru) * 2008-01-09 2011-02-28 ПиДжиИксХЭЛС ЭлЭлСи Интратекальное лечение невропатической боли агонистами ar

Also Published As

Publication number Publication date
WO2008031875A1 (en) 2008-03-20
RU2009113668A (ru) 2010-10-20
CN101511831B (zh) 2012-04-25
MA30722B1 (fr) 2009-09-01
EP2066669B1 (en) 2010-09-15
PL2066669T3 (pl) 2011-03-31
TN2009000084A1 (en) 2010-08-19
BRPI0716936A2 (pt) 2013-09-17
HRP20100694T1 (hr) 2011-01-31
NO20091244L (no) 2009-04-07
AU2007296227A1 (en) 2008-03-20
US20090325967A1 (en) 2009-12-31
DK2066669T3 (da) 2011-01-10
EP2066669A1 (en) 2009-06-10
DE602007009272D1 (de) 2010-10-28
IL197153A0 (en) 2009-11-18
US8188100B2 (en) 2012-05-29
HK1131392A1 (en) 2010-01-22
PT2066669E (pt) 2010-12-17
ATE481404T1 (de) 2010-10-15
CN101511831A (zh) 2009-08-19
AR062768A1 (es) 2008-12-03
ES2353141T3 (es) 2011-02-25
CL2007002658A1 (es) 2008-08-08
SI2066669T1 (sl) 2011-01-31
JP2010503639A (ja) 2010-02-04
TW200821324A (en) 2008-05-16
PE20081151A1 (es) 2008-10-06
KR20090040386A (ko) 2009-04-23
CR10621A (es) 2009-03-27
CA2662104A1 (en) 2008-03-20
EP1903044A1 (en) 2008-03-26
MX2009002811A (es) 2009-03-31
ZA200901036B (en) 2010-01-27

Similar Documents

Publication Publication Date Title
CY1110990T1 (el) Παραγωγα αδενοσινης ως αγωνιστες υποδοχεων α2α
CY1119865T1 (el) Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου του παρκινσον
CY1120073T1 (el) Παραγωγα πυραζολο-αμινοπυριμιδινης ως ρυθμιστες της lrrk2
CY1113323T1 (el) Ενωσεις τετραϋδροφουρο[3,4-d]διοξολανιου για χρηση στη θεραπεια ιικων μολυνσεων και καρκινου
CY1114140T1 (el) Ενωσεις 4-πυριδινονης και η χρηση αυτων για τον καρκινο
CY1108752T1 (el) Παραγωγα πουρινης δρωντα ως αγωνιστες του α2α-υποδοχεα
CY1113063T1 (el) Παραγωγα πουρινης για χρηση ως αγωνιστες των α2α υποδοχεων αδενοσινης
CY1118135T1 (el) Παραγωγα 2-(φαινυλο ή πυριδ-3-υλο) αμινοπυριμιδινης ως ρυθμιστες κινασης lrrk2 για τη θεραπευτικη αντιμετωπιση της νοσου του parkinson
CY1113339T1 (el) Ιμιδαζοκινολινες με ανοσο-ρυθμιστικες ιδιοτητες
CY1110952T1 (el) Παραγωγα κινουκλιδινης και η χρηση αυτων ως μουσκαρινικοι ανταγωνιστες υποδοχεων μ3
CY1109728T1 (el) Νεα παραγωγα υδαντοϊνης για τη θεραπεια αποφρακτικων νοσηματων της αναπνευστικης οδου
CY1117719T1 (el) Παραγωγα αμινοπυριμιδινης ως διαμορφωτες της lrrk2
HK1157337A1 (el)
CY1111747T1 (el) 8-αζαδικυκλο[3.2.1]οκτανο ενωσεις ως ανταγωνιστες μ-οπιοειδους υποδοχεα
CY1118915T1 (el) Αντιβακτηριακα αναλογα αμινογλυκοσιδης
CY1117584T1 (el) Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, cx3cr1
TN2009000180A1 (en) NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF
CY1118721T1 (el) Παραγωγα 2,3 διϋδρο-1η-ινδεν-1-υλ-2,7-διαζασπειρο[3.6]εννεανιου και η χρηση αυτων ως ανταγωνιστες ή αντιστροφοι αγωνιστες του υποδοχεα γκρελινης
CY1113846T1 (el) Παραγωγα πυριμιδινης για την θεραπευτικη αντιμετωπιση του ασθματος, copd, αλλεργικης ρινιτιδας, αλλεργικης επιπεφυκιτιδας, ατοπικης δερματιτιδας, καρκινου, ηπατιτιδας β, ηπατιτιδας c, hiv, hpv, βακτηριακων λοιμωξεων και δερματωσης
CY1117326T1 (el) Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson
CY1113269T1 (el) Παραγωγα ινδαζολυλ αμιδιου για τη θεραπευτικη αγωγη διαταραχων διαμεσολαβουμενων υπο υποδοχεα γλυκοκορτικοειδων
CY1115836T1 (el) Παραγωγα πυραζινονης και η χρηση τους στη θεραπευτικη αντιμετωπιση παθησεων των πνευμονων
CY1111705T1 (el) Παραγωγα 2-αζα-δικυκλο[3.1.0]εξανιου ως ανταγωνιστες του υποδοχεα ορεξινης
CY1107426T1 (el) Νεα παραγωγα φθοριογλυκοσιδιων απο πυραζολες, φαρμακευτικα προϊοντα που περιεχουν τις εν λογω ενωσεις και η χρηση αυτων
CY1110332T1 (el) Παραγωγα βενζιμιδαζολης, συνθεσεις που τα περιεχουν, παρασκευη αυτων και χρηση τους